<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837797</url>
  </required_header>
  <id_info>
    <org_study_id>14571A</org_study_id>
    <secondary_id>2012-001361-32</secondary_id>
    <nct_id>NCT01837797</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly
      patients with Major Depressive Disorder (MDD)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated because of recruitment challenges
  </why_stopped>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Randomisation in Depressive Symptoms During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Montgomery and Aasberg Depression Rating Scale (MADRS) total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>From randomisation to follow-up</time_frame>
    <description>15 patients were enrolled to Period 2; only 3 patients completed due to study termination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomisation in Clinical Global Impression During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Clinical Global Impression - Severity of illness (CGI-S) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomisation in Functionality Assessed by SDS During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Sheehan Disability Scale (SDS) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomisation in Social Adaptation During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Social Adaptation Self-evaluation Scale (SASS) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Based on a pre-specified decrease in MADRS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Response During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Based on a pre-specified decrease in MADRS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Based on a pre-specified MADRS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Remission During the Randomised Treatment</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>Based on a pre-specified MADRS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)</measure>
    <time_frame>From randomisation to end of treatment</time_frame>
    <description>The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily, tablets, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole 1 mg</intervention_name>
    <description>once daily dose, tablets, orally</description>
    <arm_group_label>Brexpiprazole 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole 3 mg</intervention_name>
    <description>once daily dose, tablets, orally</description>
    <arm_group_label>Brexpiprazole 3 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is an outpatient consulting a psychiatrist.

          -  The patient has a recurrent Major Depressive Disorder diagnosed according to
             DSM-IV-TR™. The current Major Depressive Episode (MDE) should be confirmed using the
             Mini International Neuropsychiatric Interview (MINI).

          -  The patient had at least one previous MDE before the age of 60 years.

          -  The patient has a moderate to severe depression and an insufficient response to at
             least one and no more than three adequate antidepressants treatments.

          -  The patient, if a woman, must have had her last natural menstruation ≥24 months prior
             to the Screening Visit.

          -  The patient, if a man, agrees to protocol-defined use of effective contraception if
             his female partner is of childbearing potential.

        Exclusion Criteria:

          -  The patient has any current psychiatric disorder or Axis I disorder (DSM-IV-TR™
             criteria), established as the primary diagnosis, other than MDD.

          -  The patient has a current Axis II (DSM-IV-TR™) diagnosis of borderline, antisocial,
             paranoid, schizoid, schizotypical or histrionic personality disorder.

          -  The patient has experienced/experiences hallucinations, delusions or any psychotic
             symptomatology in the current MDE.

          -  The patient suffers from mental retardation, organic mental disorders, or mental
             disorders due to a general medical condition (DSM-IV-TR™ criteria).

          -  The patient, in the opinion of the investigator, or according to Columbia Suicide
             Severity Rating Scale (C-SSRS), is at significant risk of suicide.

          -  The patient has had neuroleptic malignant syndrome.

          -  The patient has any relevant medical history or current presence of systemic disease.

          -  The patient has a neurodegenerative disorder.

          -  The patient has, at the Screening Visit an abnormal ECG that is, in the investigator's
             opinion, clinically significant.

          -  The patient has a history of cancer, other than basal cell or Stage 1 squamous cell
             carcinoma of the skin, that has not been in remission for &gt;5 years prior to the first
             dose of IMP.

          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol or
             is unsuitable for any reason.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US001</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US008</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001361-32/results</url>
    <description>EMA EudraCT Result Posting</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <results_first_submitted>August 17, 2015</results_first_submitted>
  <results_first_submitted_qc>February 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2016</results_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>129 patients were enrolled in the study and 128 patients received open-label treatment with one of six commercially available antidepressant antidepressant treatments (ADT) together with double-blind study treatment. Only 15 patients were randomized to Period 2 before the study was terminated; 47 patients entered Period 3.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Period 1 Placebo and ADT</title>
          <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
        </group>
        <group group_id="P2">
          <title>Period 2 Placebo and ADT</title>
          <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
        </group>
        <group group_id="P3">
          <title>Period 2 Brexpiprazole 1 mg and ADT</title>
          <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
        </group>
        <group group_id="P4">
          <title>Period 2 Brexpiprazole 3 mg and ADT</title>
          <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
        </group>
        <group group_id="P5">
          <title>Period 3 Placebo and ADT</title>
          <description>Placebo adjunct to open-label treatment with commercially available antidepressant treatment (ADT)
Placebo: Once daily, tablets, orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent before treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative or other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Period 2 Placebo and ADT</title>
          <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
        </group>
        <group group_id="B2">
          <title>Period 2 Brexpiprazole 1 mg and ADT</title>
          <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1 mg once daily, tablets, orally</description>
        </group>
        <group group_id="B3">
          <title>Period 2 Brexpiprazole 3 mg and ADT</title>
          <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 3 mg once daily, tablets, orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <description>15 patients were enrolled to Period 2; only 3 patients completed due to study termination</description>
        <time_frame>From randomisation to follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>15 patients were enrolled to Period 2; only 3 patients completed due to study termination</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Randomisation in Depressive Symptoms During the Randomised Treatment</title>
        <description>Montgomery and Aasberg Depression Rating Scale (MADRS) total score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomisation in Depressive Symptoms During the Randomised Treatment</title>
          <description>Montgomery and Aasberg Depression Rating Scale (MADRS) total score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomisation in Clinical Global Impression During the Randomised Treatment</title>
        <description>Clinical Global Impression - Severity of illness (CGI-S) score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomisation in Clinical Global Impression During the Randomised Treatment</title>
          <description>Clinical Global Impression - Severity of illness (CGI-S) score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomisation in Functionality Assessed by SDS During the Randomised Treatment</title>
        <description>Sheehan Disability Scale (SDS) total score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomisation in Functionality Assessed by SDS During the Randomised Treatment</title>
          <description>Sheehan Disability Scale (SDS) total score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomisation in Social Adaptation During the Randomised Treatment</title>
        <description>Social Adaptation Self-evaluation Scale (SASS) total score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomisation in Social Adaptation During the Randomised Treatment</title>
          <description>Social Adaptation Self-evaluation Scale (SASS) total score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response During the Randomised Treatment</title>
        <description>Based on a pre-specified decrease in MADRS total score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response During the Randomised Treatment</title>
          <description>Based on a pre-specified decrease in MADRS total score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Response During the Randomised Treatment</title>
        <description>Based on a pre-specified decrease in MADRS total score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Response During the Randomised Treatment</title>
          <description>Based on a pre-specified decrease in MADRS total score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission During the Randomised Treatment</title>
        <description>Based on a pre-specified MADRS total score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Remission During the Randomised Treatment</title>
          <description>Based on a pre-specified MADRS total score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Remission During the Randomised Treatment</title>
        <description>Based on a pre-specified MADRS total score</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Remission During the Randomised Treatment</title>
          <description>Based on a pre-specified MADRS total score</description>
          <population>Only 3 patients completed study Period 2. A total of 129 patients were enrolled when the study was terminated (Planned: 1334 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)</title>
        <description>The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour.</description>
        <time_frame>From randomisation to end of treatment</time_frame>
        <population>15 patients were enrolled to Period 2, only 3 patients completed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 Placebo and ADT</title>
            <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Brexpiprazole 1 mg and ADT</title>
            <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 1 mg once daily, tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>Period 2 Brexpiprazole 3 mg and ADT</title>
            <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available ADT
Brexpiprazole: 3 mg once daily, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)</title>
          <description>The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour.</description>
          <population>15 patients were enrolled to Period 2, only 3 patients completed due to study termination</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No suicidal ideation or behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-suicidal self-injurious behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preparatory action towards imminent suicidal behav</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not fatal suicide attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization to follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Period 2 Placebo and ADT</title>
          <description>Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Placebo: Once daily, tablets, orally</description>
        </group>
        <group group_id="E2">
          <title>Period 2 Brexpiprazole 1 mg and ADT</title>
          <description>Brexpiprazole 1 mg adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1 mg once daily, tablets, orally</description>
        </group>
        <group group_id="E3">
          <title>Period 2 Brexpiprazole 3 mg and ADT</title>
          <description>Brexpiprazole 3 mg adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 3 mg once daily, tablets, orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Email contact via H. Lundbeck A/S</name_or_title>
      <organization>Study Director</organization>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

